Drug Profile
Vanzacaftor-Vertex Pharmaceuticals
Alternative Names: Vanzacaftor; VX 121Latest Information Update: 08 Aug 2023
Price :
$50
*
At a glance
- Originator Vertex Pharmaceuticals
- Class Antifibrotics; Ethers; Heterocyclic compounds with 4 or more rings; Pyrazoles; Pyridines; Pyrrolidines; Small molecules; Spiro compounds
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cystic fibrosis
Most Recent Events
- 08 Aug 2023 Chemical structure information added
- 14 Jun 2023 Vertex Pharmaceuticals completed a phase-I trial in Cystic fibrosis (In volunteers, In adults, Monotherapy) in USA (PO) (NCT05867147)
- 26 Apr 2023 Phase-I clinical trials in Cystic fibrosis (In volunteers, In adults, Monotherapy) in USA (PO) (NCT05867147)